^
Association details:
| Biomarker: | HER-2 A1170P |
|---|---|
| Cancer: | HER2 Positive Breast Cancer |
| Drug: | Herceptin (trastuzumab) (HER2 inhibitor) + Perjeta (pertuzumab) (HER2 dimerization inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
HER2 and BARD1 Polymorphisms in Early HER2-Positive Breast Cancer Patients: Relationship with Response to Neoadjuvant Anti-HER2 Treatment
Published date:
01/26/2023
Excerpt:
Fifty female patients diagnosed with HER2-positive breast cancer were treated...The SNPs rs1058808 (HER2Ala1170Pro) and rs2070096 (BARD1Thr351=) could be considered as potential biomarkers of a good response to neoadjuvant treatment with trastuzumab and pertuzumab for early BC patients.
DOI:
10.3390/cancers15030763
